Science AI Journal
Medicine · Research topic

Open research questions in Neuroendocrine Tumor Research Advances

395 gap statements mined from Neuroendocrine Tumor Research Advances papers in our 7.9M-paper local library, which holds 1,725 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Neuroendocrine Tumor Research Advances? See the ranked Medicine journals.

What the literature leaves open

  • The study highlights the need for long-term clinical, biochemical, and imaging follow-up of patients with MEN1 syndrome.

    Genetic Features in a Case Series of Gastro-entero-pancreatic Neuroendocrine Tumors · 2026 · DOI

  • The prevalence and association of bone metastases with survival in NETs of unknown primary remain insufficiently characterized. The reported prevalence of bone metastases in NETs varies widely, depending on tumor entity, disease stage, and imaging modalities used for detection.

    Bone metastases identify a high-risk subgroup in metastatic neuroendocrine tumors with particular relevance in NETs of unknown primary · 2026 · DOI

  • The disease is rare and has a limited number of documented cases. The study had to rely on a single family with multiple affected members. The analysis of somatic mutations in tumour samples was challenging due to the limited amount of tissue available.

    Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations · 2025 · DOI

  • The incidence of pancreatic neuroendocrine neoplasms (NENs) is rising; whether this reflects a true increase in disease occurrence or improved detection remains uncertain.

    Determinants of incidence trends in pancreatic neuroendocrine neoplasms · 2026 · DOI

  • While retrospective studies suggest improved survival and possible reduction of local complications, the evidence is limited by heterogeneity, selection bias, and an absence of prospective validation.

    Controversies in neuroendocrine neoplasms: An European Neuroendocrine Tumor Society position statement on the role of surgery of the primary tumour in metastatic small intestinal and pancreatic neuroendocrine tumours · 2026 · DOI

  • The role of primary tumour resection (PTR) in metastatic small intestinal (SiNETs) and pancreatic neuroendocrine tumours (PanNETs) remains debated.

    Controversies in neuroendocrine neoplasms: An European Neuroendocrine Tumor Society position statement on the role of surgery of the primary tumour in metastatic small intestinal and pancreatic neuroendocrine tumours · 2026 · DOI

  • Pancreatic neuroendocrine tumors (PanNETs) are increasingly detected, and the optimal extent of resection remains uncertain because perioperative burden and oncologic assessment may differ by procedure.

    Procedure‐specific morbidity and pathologic assessment after resection of small (≤20 mm) pancreatic neuroendocrine tumors · 2026 · DOI

  • Although NENs are intrinsically capable of producing bioactive substances leading to PNS, the true prevalence of PNS in NENs remains uncertain and is likely underestimated.

    “Paraneoplastic syndromes secondary to Νeuroendocrine Νeoplasms” · 2026 · DOI

  • Tumor size is the main prognostic factor, yet optimal management for tumors >1 cm remains uncertain.

    Management Strategies and Outcomes for Type 1 Gastric Neuroendocrine Tumors Measuring More Than 1 cm · 2026 · DOI

  • While guidelines suggest minimum lymph node yields (LNY), the independent prognostic relevance of LNY and lymph node ratio (LNR) regarding recurrence remains uncertain in contemporary cohorts.

    Biological and comorbidity factors outweigh lymph node metrics in predicting outcomes after small-bowel neuroendocrine tumour resection · 2026 · DOI

  • Bone metastases (BM) are an increasingly recognized manifestation of advanced neuroendocrine tumors (NETs), but their prevalence and association with survival in NETs of unknown primary (CUP NET) remain insufficiently characterized.

    Bone metastases identify a high-risk subgroup in metastatic neuroendocrine tumors with particular relevance in NETs of unknown primary · 2026 · DOI

  • Compared with systemic therapy for NETs, surgical evidence is sparse and heterogeneous.

    Surgical management of small intestinal neuroendocrine tumours · 2026 · DOI

  • Primary tumour resection of an asymptomatic SI-NET with unresectable stage IV disease remains controversial.

    Surgical management of small intestinal neuroendocrine tumours · 2026 · DOI

  • Well-differentiated grade 3 neuroendocrine tumors (NETs) have recently been described as a distinct category, and randomized data regarding efficacy of therapy for these patients are scarce.

    Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602) · 2026 · DOI

  • Hepatic arterial embolization reduces liver tumor burden and hormonal secretion in neuroendocrine tumors, but its safety in patients with carcinoid heart disease is underexplored, and current guidelines suggest managing the cardiac disease first.

    Hepatic arterial embolization procedures in neuroendocrine tumors with carcinoid heart disease: a retrospective single-center study on safety and feasibility · 2026 · DOI

  • Effective treatment of metastatic neuroendocrine tumors (NETs) is limited by a lack of targeted therapies and clinically useful predictive biomarkers.

    PSIP1::TBL1X : a recurrent gene fusion in pancreatic neuroendocrine tumors · 2026 · DOI

  • However, in the absence of high-quality comparative data, the optimal selection among these approaches remains uncertain.

    Gastric Neuroendocrine Tumors: Current Evidence and Challenges in Endoscopic Management · 2026 · DOI

  • The role of endoscopic papillectomy (EP) for ampullary neuroendocrine tumors (Amp-NETs) remains uncertain due to concerns regarding lymph node (LN) metastasis and recurrence.

    Long‐Term Outcomes Following Endoscopic Papillectomy for Ampullary Neuroendocrine Tumors · 2025 · DOI

  • While international guidelines provide criteria for endoscopic management, several aspects remain controversial due to limited high-quality evidence.

    Controversies in NEN : An ENETS position statement on the endoscopic management of localised gastric, duodenal and rectal neuroendocrine neoplasms · 2025 · DOI

  • There is limited data on the use of immunotherapy and targeted therapy in this disease group to date, and some available evidence will be presented.

    Controversies in NEN : An ENETS position statement on the treatment of patients with Grade 3 well‐differentiated neuroendocrine tumours of the gastro‐enteropancreatic tract · 2025 · DOI

  • The tool is intended as an additional method where other diagnostic modalities remain inconclusive regarding the location of the primary tumor.

    A new, machine learning‐based approach to metastatic neuroendocrine tumors of unknown origin · 2026 · DOI

  • Although first-line chemoimmunotherapy has improved survival in SCLC, its role in PanNEC is not well defined.

    Outcomes of Chemoimmunotherapy in Metastatic Pancreatic Neuroendocrine Carcinoma: A Single-Center Clinicopathologic Study · 2026 · DOI

  • While VIP concentrations are elevated in VIPoma, the optimal threshold for diagnostic purposes is not well defined.

    Elevated vasoactive intestinal peptide concentrations poorly predict VIPoma · 2026 · DOI

  • Ectopic hormone secretion from neuroendocrine neoplasms in the lung (lung-NENs) is rare and poorly explored.

    Hormone secretion predicts poor prognosis in lung neuroendocrine neoplasms · 2026 · DOI

  • No external funding source for this study, - Limited to a single family with multiple members presenting with GCNH, - No dedicated imaging of the pancreas has been performed for some family…

    Familial Mahvash disease with metastatic pancreatic NET and MEN1 mutations · 2025 · DOI

Most-cited papers in Neuroendocrine Tumor Research Advances

Most recent work

Find a gap in your own Neuroendocrine Tumor Research Advances sub-topic

This page shows what the Neuroendocrine Tumor Research Advances literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,200 open questions
Dementia and Cognitive Impairment Research
2,789 open questions
Substance Abuse Treatment and Outcomes
2,285 open questions
Cancer Immunotherapy and Biomarkers
2,273 open questions
Liver Disease Diagnosis and Treatment
2,102 open questions
Sports Performance and Training
1,952 open questions
Parkinson's Disease Mechanisms and Treatments
1,915 open questions
Mosquito-borne diseases and control
1,849 open questions
Open questions raised by papers listed on this page include: (1) The prevalence and association of bone metastases with survival in NETs of unknown primary remain insufficiently characterized (“Bone metastases identify a high-risk subgroup in metastatic neuroendocrine…”, 2026); (2) Primary tumour resection of an asymptomatic SI-NET with unresectable stage IV disease remains controversial (“Surgical management of small intestinal neuroendocrine tumours”, 2026); (3) Well-differentiated grade 3 neuroendocrine tumors (NETs) have recently been described as a distinct category, and randomized data regarding efficacy of therapy for these patients are scarce (“Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of…”, 2026); (4) Effective treatment of metastatic neuroendocrine tumors (NETs) is limited by a lack of targeted therapies and clinically useful predictive biomarkers (“PSIP1::TBL1X : a recurrent gene fusion in pancreatic neuroendocrine tumors”, 2026); (5) While international guidelines provide criteria for endoscopic management, several aspects remain controversial due to limited high-quality evidence (“Controversies in NEN : An ENETS position statement on the endoscopic management…”, 2025). 395 gap statements have been mined from Neuroendocrine Tumor Research Advances papers in our 7.9M-paper local library, which holds 1,725 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.